Published in Ann Neurol on May 01, 2003
Accuracy of magnetic resonance imaging for the diagnosis of multiple sclerosis: systematic review. BMJ (2006) 2.95
MRI in multiple sclerosis: current status and future prospects. Lancet Neurol (2008) 2.08
Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry (2005) 1.59
FLAIR imaging for multiple sclerosis: a comparative MR study at 1.5 and 3.0 Tesla. Eur Radiol (2005) 1.08
Imaging of multiple sclerosis: role in neurotherapeutics. NeuroRx (2005) 0.98
Interobserver agreement on the radiological criteria of the International Panel on the diagnosis of multiple sclerosis. Eur Radiol (2006) 0.80
Loss of vision: imaging the visual pathways. Eur Radiol (2005) 0.77
Clinically Isolated Syndromes: Clinical Characteristics, Differential Diagnosis, and Management. Noro Psikiyatr Ars (2015) 0.75
Multiple sclerosis: should MR criteria for dissemination in time be less stringent. Ann Neurol (2004) 0.75
Current issues in immunomodulatory treatment of multiple sclerosis--a practical approach. J Neurol (2006) 0.75
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol (2011) 25.66
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol (2005) 24.22
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med (2006) 11.29
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med (2012) 6.51
A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med (2003) 5.77
A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med (2002) 3.74
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet (2008) 3.68
MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol (2007) 3.47
Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann Neurol (2005) 3.45
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol (2009) 3.42
Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol (2004) 3.23
Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol (2012) 3.15
Functional-anatomical validation and individual variation of diffusion tractography-based segmentation of the human thalamus. Cereb Cortex (2004) 3.03
Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations. Lancet Neurol (2007) 2.53
The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol (2005) 2.44
MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation". Lancet Neurol (2006) 2.44
Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol (2009) 2.43
Diffusion tensor imaging of post mortem multiple sclerosis brain. Neuroimage (2006) 2.35
Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain (2002) 2.30
Neuroplasticity predicts outcome of optic neuritis independent of tissue damage. Ann Neurol (2010) 2.24
An investigation of the retinal nerve fibre layer in progressive multiple sclerosis using optical coherence tomography. Brain (2007) 2.18
Initial demonstration of in vivo tracing of axonal projections in the macaque brain and comparison with the human brain using diffusion tensor imaging and fast marching tractography. Neuroimage (2002) 2.14
MRI in multiple sclerosis: current status and future prospects. Lancet Neurol (2008) 2.08
Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med (2007) 2.06
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol (2010) 2.03
Quality of life measurement after stroke: uses and abuses of the SF-36. Stroke (2002) 2.00
Motor system activation after subcortical stroke depends on corticospinal system integrity. Brain (2006) 1.99
Head size, age and gender adjustment in MRI studies: a necessary nuisance? Neuroimage (2010) 1.99
Tournay's description of anisocoria on lateral gaze: reaction, myth, or phenomenon? Neurology (2014) 1.98
Retrograde trans-synaptic retinal ganglion cell loss identified by optical coherence tomography. Brain (2009) 1.97
Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol (2008) 1.91
Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol (2007) 1.88
Quantitative magnetic resonance of postmortem multiple sclerosis brain before and after fixation. Magn Reson Med (2008) 1.82
Investigating cervical spinal cord structure using axial diffusion tensor imaging. Neuroimage (2002) 1.76
Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain (2004) 1.71
Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol (2012) 1.70
Effect sizes can be misleading: is it time to change the way we measure change? J Neurol Neurosurg Psychiatry (2010) 1.70
Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain (2003) 1.62
The evolution of prefrontal inputs to the cortico-pontine system: diffusion imaging evidence from Macaque monkeys and humans. Cereb Cortex (2005) 1.61
Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported. J Neurol (2013) 1.59
Patient-based outcomes of cervical dystonia: a review of rating scales. Mov Disord (2004) 1.59
Disability, atrophy and cortical reorganization following spinal cord injury. Brain (2011) 1.58
Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol (2002) 1.57
Quantitative magnetization transfer imaging in postmortem multiple sclerosis brain. J Magn Reson Imaging (2007) 1.54
Reducing the impact of white matter lesions on automated measures of brain gray and white matter volumes. J Magn Reson Imaging (2010) 1.54
Exploring rating scale responsiveness: does the total score reflect the sum of its parts? Neurology (2004) 1.54
Optic nerve diffusion tensor imaging in optic neuritis. Neuroimage (2005) 1.54
Characterizing function-structure relationships in the human visual system with functional MRI and diffusion tensor imaging. Neuroimage (2004) 1.52
The therapeutic potential of cannabis. Lancet Neurol (2003) 1.49
A serial study of retinal changes following optic neuritis with sample size estimates for acute neuroprotection trials. Brain (2010) 1.48
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol (2009) 1.46
Functional anatomy of interhemispheric cortical connections in the human brain. J Anat (2006) 1.45
High field (9.4 Tesla) magnetic resonance imaging of cortical grey matter lesions in multiple sclerosis. Brain (2010) 1.42
Optic nerve atrophy and retinal nerve fibre layer thinning following optic neuritis: evidence that axonal loss is a substrate of MRI-detected atrophy. Neuroimage (2006) 1.41
The relationship between brain activity and peak grip force is modulated by corticospinal system integrity after subcortical stroke. Eur J Neurosci (2007) 1.34
A serial MRI study following optic nerve mean area in acute optic neuritis. Brain (2004) 1.32
Optical coherence tomography of the retina: applications in neurology. Curr Opin Neurol (2010) 1.32
ADC mapping of the human optic nerve: increased resolution, coverage, and reliability with CSF-suppressed ZOOM-EPI. Magn Reson Med (2002) 1.30
Improved detection of cortical MS lesions with phase-sensitive inversion recovery MRI. J Neurol Neurosurg Psychiatry (2012) 1.29
Assessing structure and function of the afferent visual pathway in multiple sclerosis and associated optic neuritis. J Neurol (2009) 1.29
Optic radiation changes after optic neuritis detected by tractography-based group mapping. Hum Brain Mapp (2005) 1.29
The influence of time after stroke on brain activations during a motor task. Ann Neurol (2004) 1.27
A study of the mechanisms of normal-appearing white matter damage in multiple sclerosis using diffusion tensor imaging--evidence of Wallerian degeneration. J Neurol (2003) 1.26